Enveric Biosciences, Inc. (ENVB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29405E5050
Enveric Biosciences, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -9.63 m USD | -8.77 m USD |
| EBIT | -9.57 m USD | -8.77 m USD |
| Net income | -9.57 m USD | -8.77 m USD |
| Diluted EPS – continuing operations | -19.04 USD | -36.24 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
More stocks
- CNS Pharmaceuticals, Inc. (CNSP)
- AiXin Life International, Inc. (AIXN)
- Saker Aviation Services, Inc. (SKAS)
- TAP REAL ESTATE TECHNOLOGIES, INC. (RWAX)
- Financial Gravity Companies, Inc. (FGCO)
- Innovative Eyewear Inc (LUCY)
- ADM ENDEAVORS, INC. (ADMQ)
- LataMed AI Corp. (LMED)
- GAXOS.AI INC. (GXAI)
- Zeo ScientifiX, Inc. (ZEOX)
- Rocky Mountain Chocolate Factory, Inc. (RMCF)
- Adaptimmune Therapeutics PLC (ADAPY)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.